Cell therapy for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy (HS-IT101) for people with advanced clear cell renal cell carcinoma, a type of kidney cancer that has spread. The treatment aims to boost the immune system to fight the cancer. Participants must be in good general health and have had no recent cancer treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced clear cell renal cell carcinoma, confirmed by biopsy or other tests.
- You must have at least one measurable tumor on imaging scans.
- You must have good daily function (ECOG 0 or 1).
- You must not have had cancer treatment within the past 4 weeks, and any side effects from previous treatment must have resolved to mild or less (except hair loss).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This trial tests a new treatment using a patient's own immune cells, called CAR-NKT cells, which are designed to target and attack kidney cancer cells that have a specific marker called CD70. It may be an option for people whose clear cell kidney cancer has come back or spread after at least one prior treatment.
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.